{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:31Z","timestamp":1790085691295,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00597-7","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T13:01:52Z","timestamp":1715259712000},"page":"535-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-9428","authenticated-orcid":false,"given":"Stacey L.","family":"Clardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Fam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kielhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"597_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm. 2012;9:14.","journal-title":"J Neuroinflamm"},{"issue":"3","key":"597_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000965","volume":"8","author":"JW Hyun","year":"2021","unstructured":"Hyun JW, Kim Y, Kim SY, Lee MY, Kim SH, Kim HJ. Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e965.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"597_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"10","key":"597_CR4","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088\u201394.","journal-title":"J Neurol"},{"issue":"1","key":"597_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.nrl.0000250927.21903.f8","volume":"13","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist. 2007;13(1):2\u201311.","journal-title":"Neurologist"},{"issue":"4","key":"597_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012;109(4):1245\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"597_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/WNO.0b013e31825662f1","volume":"32","author":"MJ Morrow","year":"2012","unstructured":"Morrow MJ, Wingerchuk D. Neuromyelitis optica. J Neuroophthalmol. 2012;32(2):154\u201366.","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"597_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60\u20137.","journal-title":"Lancet Neurol"},{"issue":"2","key":"597_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000947","volume":"8","author":"SH Kim","year":"2021","unstructured":"Kim SH, Jang H, Park NY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e947.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"597_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577467","volume":"351","author":"T Akaishi","year":"2021","unstructured":"Akaishi T, Misu T, Takahashi T, et al. Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. J Neuroimmunol. 2021;351:577467.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"597_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","volume":"19","author":"S Huda","year":"2019","unstructured":"Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169\u201376.","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"597_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","volume":"15","author":"T Duan","year":"2018","unstructured":"Duan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflamm. 2018;15(1):294.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"597_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.","journal-title":"Nat Rev Dis Primers"},{"key":"597_CR14","unstructured":"SOLIRIS\u00ae (eculizumab). Prescribing Information. Alexion Pharmaceuticals, Inc., Boston, MA; 2020 November."},{"key":"597_CR15","unstructured":"ENSPRYNG\u00ae (satralizumab-mwge). Prescribing Information. Genentech, Inc., San Francisco; 2022 March."},{"key":"597_CR16","unstructured":"Uplizna\u00ae (inebilizumab-cdon). Prescribing Information. Horizon Therapeutics, Dublin, 2021 July."},{"key":"597_CR17","unstructured":"Soliris: product information. European Medicines Agency, London, 2021."},{"issue":"22","key":"597_CR18","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"597_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase\u00a03 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"issue":"10206","key":"597_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase\u00a02\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"key":"597_CR21","unstructured":"Update on US regulatory review of ULTOMIRIS\u00ae in NMOSD [press release]. AstraZeneca, 6 September 2023."},{"issue":"6","key":"597_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"key":"597_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/9781118951651.ch4","volume-title":"Network meta-analysis for decision making","author":"S Dias","year":"2018","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Generalised linear models. In: Dias S, Welton NJ, Jansen JP, Sutton AJ, editors. Network meta-analysis for decision making. Wiley; 2018. p. 93\u2013153."},{"issue":"4","key":"597_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417\u201328.","journal-title":"Value Health"},{"issue":"5","key":"597_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607\u201317.","journal-title":"Med Decis Mak"},{"issue":"4","key":"597_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"issue":"11","key":"597_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"1","key":"597_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311.","journal-title":"Intern Emerg Med"},{"issue":"26","key":"597_CR29","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1002\/sim.9562","volume":"41","author":"T Evrenoglou","year":"2022","unstructured":"Evrenoglou T, White IR, Afach S, Mavridis D, Chaimani A. Network meta-analysis of rare events using penalized likelihood regression. Stat Med. 2022;41(26):5203\u201319.","journal-title":"Stat Med"},{"issue":"1","key":"597_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","volume":"57","author":"G Heinze","year":"2001","unstructured":"Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57(1):114\u20139.","journal-title":"Biometrics"},{"issue":"4","key":"597_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/biom.12528","volume":"72","author":"DY Lin","year":"2016","unstructured":"Lin DY, Dai L, Cheng G, Sailer MO. On confidence intervals for the hazard ratio in randomized clinical trials. Biometrics. 2016;72(4):1098\u2013102.","journal-title":"Biometrics"},{"issue":"4","key":"597_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol"},{"issue":"13","key":"597_CR33","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1177\/1352458521988926","volume":"27","author":"BA Cree","year":"2021","unstructured":"Cree BA, Bennett JL, Kim HJ, et al. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021;27(13):2052\u201361.","journal-title":"Mult Scler"}],"updated-by":[{"DOI":"10.1007\/s40120-024-00638-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00597-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:17:15Z","timestamp":1718432235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00597-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00597-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40120-024-00638-1","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-024-00638-1","URL":"https:\/\/doi.org\/10.1007\/s40120-024-00638-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stacey L. Clardy is an employee of the University of Utah and the Salt Lake City VA. She and her institution have received research support from NIH\/NINDS (U01, The ExTINGUISH Trial), the Western Institute for Veteran Research, the Siegel Rare Neuroimmune Association, the Immune Deficiency Foundation, Viela Bio\/Horizon, Alexion\/AstraZeneca, the Barbara Gural Steinmetz Foundation, and the Sumaira Foundation for NMO, and consulting\/advisory board fees from Alexion, VielaBio\/Horizon, and Genentech\/Roche. Sean J. Pittock has received personal compensation for serving on scientific advisory boards for F. Hoffmann-La Roche (which manufactures satralizumab, an approved targeted therapy for NMOSD) and his institution has received grants; his institution has received grants, personal fees, nonfinancial support, research support, and compensation for serving as a consultant for Alexion, AstraZeneca Rare Disease (which holds the patent rights to ravulizumab and eculizumab). He holds Patent # 9,891,219B2, Application # 12\u2013573,942, Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an Individual That Is Aquaporin-4 (AQP4)-IgG Autoantibody Positive, which has been issued and for which he has received royalties. He also reports grants, personal fees, nonfinancial support, and other support from Horizon, MedImmune (which produces inebilizumab). Orhan Aktas reports grants from the German Ministry of Education and Research (BMBF) and the German Research Foundation (DFG); grants and personal fees from Biogen, Genzyme, Novartis, and Teva, and personal fees from Alexion, Almirall, Bristol Myers Squibb, Horizon Therapeutics, Merck Serono, and Roche, and is a member of the European Reference Network for Rare Eye Diseases (ERN-EYE), co-funded by the Health Program of the European Union under the Framework Partnership Agreement No 739434 \u2018ERN-EYE\u2019. Jin Nakahara reports personal fees from AbbVie, Alexion Pharma GK, Asahi Kasei Medical, Biogen, Bristol Myers Squibb, Chugai, CSL Behring, Daiichi Sankyo, Eisai, Kyorin, Mitsubishi Tanabe Pharma, Novartis, Otsuka, Roche, Takeda, and Teijin Pharma; research scholarships from AbbVie, Boehringer Ingelheim, Chugai, Daiichi Sankyo, EA Pharma, Eisai, JB, Mitsubishi Tanabe Pharma, Otsuka, Shionogi, Sumitomo Pharma, Teijin Pharma, and Tsumura; and grants from the Ministry of Education, Science and Technology of Japan, the MHLW, and Biogen. Noriko Isobe reports speaker honorarium from Alexion Pharma GK, Biogen Japan, Chugai, CSL Behring, Daiichi Sankyo, Eisai, Mitsubishi Tanabe Pharma, Novartis, Takeda Pharma, Teijin Pharma; research grants from Teijin Pharma, Chugai; and collaborative research with Biogen Japan. Diego Centonze is an employee of the University of Rome Tor Vergata. Sami Fam is an employee and stockholder of Alexion Pharmaceuticals. Adrian Kielhorn is an employee and stockholder of Alexion Pharmaceuticals. Jeffrey Yu is an employee and stockholder of Alexion Pharmaceuticals. Jeroen Jansen is an employee of PRECISIONheor, a consultancy firm, which received funding from Alexion Pharmaceuticals to support this work. Ina Zhang is an employee of PRECISIONheor, a consultancy firm, which received funding from Alexion Pharmaceuticals to support this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}